Rectal cancer: chemotherapy or chemoradiation first?
Real sources · Illustrative request · Sample version
Customer question
Illustrative situation: a patient with stage II/III rectal cancer receives two total-neoadjuvant sequence proposals and values organ preservation.
What do the sequences show about organ preservation, disease-free survival and surveillance?
Compare goals and prerequisites. OPRA organ-preservation results are not an individual probability of cure.
OPRA: 5-year TME-free survival
Published estimates; TME-free survival is not overall survival. Randomized phase II trial; sequence did not show a survival difference.
Analysis excerpt
| Check | Finding / sample content | Use |
|---|---|---|
| Study answer | Two sequences examined organ preservation and oncologic outcomes | Keep organ preservation separate from disease-free survival |
| Patient fit | MRI, response assessment and surveillance feasibility are absent here | Ask the treating oncology/surgical team to review |
| Consultation question | When is watch-and-wait appropriate and how is failure managed? | Confirm monitoring and salvage plans before shared decisions |
Delivery manifest
| File | Format | Contents |
|---|---|---|
| Route comparison example | Two routes with population, outcomes, risks and missing facts | |
| Consultation questions and source table | PDF / CSV | Clinician source locations; family explanation of endpoints and open questions |
This is an illustrative formal delivery manifest. This pack supplies an HTML report, CSV tables and a source register. Agree formal formats, quantities and scope in the quote.
Acceptance criteria
- Each comparison row maps to a patient record or reference, with search cutoff, population fit and remaining gaps. Drafts do not make decisions reserved for clinicians and patients.
Sources
- OPRA randomized phase II trial: long-term results (JCO, 2024)
https://ascopubs.org/doi/10.1200/JCO.23.01208